TG Therapeutics Inc. (TGTX)
TG Therapeutics Statistics
Share Statistics
TG Therapeutics has 157.07M shares outstanding. The number of shares has increased by 1.64% in one year.
| Shares Outstanding | 157.07M |
| Shares Change (YoY) | 1.64% |
| Shares Change (QoQ) | 0.9% |
| Owned by Institutions (%) | 66.74% |
| Shares Floating | 141.43M |
| Failed to Deliver (FTD) Shares | 15.17K |
| FTD / Avg. Volume | 0.57% |
Short Selling Information
The latest short interest is 27.63M, so 17.75% of the outstanding shares have been sold short.
| Short Interest | 27.63M |
| Short % of Shares Out | 17.75% |
| Short % of Float | 19.66% |
| Short Ratio (days to cover) | 10.75 |
Valuation Ratios
The PE ratio is 187.06 and the forward PE ratio is 35.59. TG Therapeutics's PEG ratio is 2.36.
| PE Ratio | 187.06 |
| Forward PE | 35.59 |
| PS Ratio | 13.29 |
| Forward PS | 3.9 |
| PB Ratio | 19.67 |
| P/FCF Ratio | -107.96 |
| PEG Ratio | 2.36 |
Enterprise Valuation
TG Therapeutics has an Enterprise Value (EV) of 4.45B.
| EV / Sales | 13.52 |
| EV / EBITDA | 89.13 |
| EV / EBIT | -109.78 |
| EV / FCF | -109.78 |
Financial Position
The company has a current ratio of 6.25, with a Debt / Equity ratio of 1.14.
| Current Ratio | 6.25 |
| Quick Ratio | 5.03 |
| Debt / Equity | 1.14 |
| Debt / EBITDA | 5.08 |
| Debt / FCF | -6.26 |
| Interest Coverage | 1.75 |
Financial Efficiency
Return on Equity is 10.52% and Return on Invested Capital is 7.85%.
| Return on Equity | 10.52% |
| Return on Assets | 4.05% |
| Return on Invested Capital | 7.85% |
| Revenue Per Employee | $973.38K |
| Profits Per Employee | $69.18K |
| Employee Count | 338 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 0.35 |
Taxes
| Income Tax | 2.21M |
| Effective Tax Rate | 8.64% |
Stock Price Statistics
The stock price has increased by 175.19% in the last 52 weeks. The beta is 2.3, so TG Therapeutics's price volatility has been higher than the market average.
| Beta | 2.3 |
| 52-Week Price Change | 175.19% |
| 50-Day Moving Average | 34.91 |
| 200-Day Moving Average | 27.53 |
| Relative Strength Index (RSI) | 55.82 |
| Average Volume (20 Days) | 2.66M |
Income Statement
In the last 12 months, TG Therapeutics had revenue of 329M and earned 23.38M in profits. Earnings per share was 0.16.
| Revenue | 329M |
| Gross Profit | 290.52M |
| Operating Income | 41.93M |
| Net Income | 23.38M |
| EBITDA | 49.9M |
| EBIT | 49.62M |
| Earnings Per Share (EPS) | 0.16 |
Balance Sheet
The company has 179.89M in cash and 253.72M in debt, giving a net cash position of -73.83M.
| Cash & Cash Equivalents | 179.89M |
| Total Debt | 253.72M |
| Net Cash | -73.83M |
| Retained Earnings | -1.53B |
| Total Assets | 577.69M |
| Working Capital | 475.68M |
Cash Flow
In the last 12 months, operating cash flow was -40.52M and capital expenditures 0, giving a free cash flow of -40.52M.
| Operating Cash Flow | -40.52M |
| Capital Expenditures | 0 |
| Free Cash Flow | -40.52M |
| FCF Per Share | -0.28 |
Margins
Gross margin is 88.3%, with operating and profit margins of 12.74% and 7.11%.
| Gross Margin | 88.3% |
| Operating Margin | 12.74% |
| Pretax Margin | 7.78% |
| Profit Margin | 7.11% |
| EBITDA Margin | 15.17% |
| EBIT Margin | 12.74% |
| FCF Margin | -12.32% |
Dividends & Yields
TGTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 0.53% |
| FCF Yield | -0.93% |
Analyst Forecast
The average price target for TGTX is $41.5, which is 4.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $41.5 |
| Price Target Difference | 4.2% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Apr 30, 2012. It was a backward split with a ratio of 4:225.
| Last Split Date | Apr 30, 2012 |
| Split Type | backward |
| Split Ratio | 4:225 |
Scores
| Altman Z-Score | 8.5 |
| Piotroski F-Score | 4 |